Table 3 Course of liver enzymes in patients initially treated with D-penicillamine, grouped by treatment response
Median UI/L (range) | P value | |||
|---|---|---|---|---|
ALT (UI/L) | Baseline | Responder | 201 (23–514) | .19 |
Non-responder | 398 (173–582) | |||
6 months | Responder | 122 (32–576) | .26 | |
Non-responder | 236 (165–279) | |||
12 months | Responder | 60 (20–178) | ≤.001 | |
Non-responder | 91 (83–166) | |||
24 months | Responder | 46 (14–76) | ≤.001 | |
Non-responder | 205 (65–245) | |||
>36 months | Responder | 36 (12–77) | ≤.001 | |
Non-responder | 165 (91–377) | |||
AST(UI/L) | Baseline | Responder | 114 (27–227) | .24 |
Non-responder | 117 (72–205) | |||
6 months | Responder | 60 (26–198) | .23 | |
Non-responder | 94 (89–115) | |||
12 months | Responder | 43 (22–74) | .18 | |
Non-responder | 60 (47–60) | |||
24 months | Responder | 38 (24–51) | ≤.001 | |
Non-responder | 100 (85–114) | |||
>36 months | Responder | 32 (20–61) | .004 | |
Non-responder | 66 (40–76) | |||
GGT(UI/L) | Baseline | Responder | 68 (11–227) | .54 |
Non-responder | 74 (48–267) | |||
6 months | Responder | 39 (14–119) | .64 | |
Non-responder | 59 (49–65) | |||
12 months | Responder | 27 (13–57) | .19 | |
Non-responder | 42 (36–48) | |||
24 months | Responder | 24 (12–44) | .29 | |
Non-responder | 31 (31–32) | |||
>36 months | Responder | 17 (12–40) | .29 | |
Non-responder | 31 (25–41) |